surmount-1 trial tirzepatide non-diabetic obesity weight loss nondiabetic For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults Tirzepatide after intensive lifestyle intervention – 💊 Could a new medication

This fundamental difference drives the efficacy gap

To schedule an appointment or get your questions answered, visit us online or call (832) 548-5000

Divide the dose already prescribed in mg by the pharmacy-label concentration in mg/mL

this adds bulk and helps food pass through the digestive tract more efficiently, supporting regularity

The MHRA approved the Wegovy pill in June 2026, the first weight-loss tablet licensed in the UK, and it reached private providers, including Second Nature, in July 2026

Important Note: It's best to work with a registered dietitian or nutritionist to create a personalized meal plan that meets your individual needs and preferences